Lighthouse Pharmaceuticals

Executive Summary

Lighthouse Pharmaceuticals is a private, clinical-stage biopharmaceutical company pioneering a precision medicine approach to Alzheimer's disease. Its lead asset, LHP588, is an oral small molecule in Phase 2 development specifically for patients with P. gingivalis-positive Alzheimer's disease, addressing a biomarker-defined subpopulation with high unmet need. The pathogen P. gingivalis has been implicated in neuroinflammation and amyloid pathology, positioning LHP588 as a potentially disease-modifying therapy. The company is headquartered in San Diego and has not disclosed total funding or valuation. With no approved therapies for this subtype, success in Phase 2 could unlock significant value and attract partnership interest.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim efficacy data for LHP58840% success
• Q2 2027Phase 2 top-line results in P. gingivalis-positive Alzheimer's35% success
• Q3 2026Series B or strategic partnership announcement50% success